The molecular diagnostic products and services supplied by MolecularMD are specifically intended to help navigate the significant challenges facing developers of targeted cancer treatments. Our assays are designed to meet clinical performance requirements and, at the same time, address the healthcare considerations of patients, doctors, and payors.
Together with our pharmaceutical clients, we aim to better understand the link between molecular response and improved survival.
A Conversation With Brian J. Druker, M.D.
Researcher Behind the Drug Gleevec - By CLAUDIA DREIFUS
http://www.nytimes.com/2009/11/03/science/03conv.html?ref=science
MolecularMD Establishes New Operations Facility to Support Growth in Personalized Cancer Medicine Business
